These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37798673)

  • 1. Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
    Ali SA; Shell J; Harris R; Bedder M
    Harm Reduct J; 2023 Oct; 20(1):144. PubMed ID: 37798673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
    Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
    J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
    Kohan LR; Elmofty D; Pena I; Liao C
    J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose.
    Follman S; Arora VM; Lyttle C; Moore PQ; Pho MT
    JAMA Netw Open; 2019 May; 2(5):e193209. PubMed ID: 31050777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
    Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
    Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in naloxone prescriptions in a University Hospital during the COVID-19 pandemic.
    Chieh K; Patel I; Walter L; Li L
    Harm Reduct J; 2022 Jul; 19(1):84. PubMed ID: 35883136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. URINE TOXICOLOGY PROFILES OF EMERGENCY DEPARTMENT PATIENTS WITH UNTREATED OPIOID USE DISORDER: A MULTI-SITE VIEW.
    Cowan E; Perrone J; Dziura J; Edelman EJ; Hawk K; Herring A; McCormack R; Murphy A; Phadke M; Fiellin DA; D'Onofrio G
    J Emerg Med; 2023 Oct; 65(4):e357-e365. PubMed ID: 37716904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for severe respiratory depression from prescription opioid overdose.
    Fox LM; Hoffman RS; Vlahov D; Manini AF
    Addiction; 2018 Jan; 113(1):59-66. PubMed ID: 28646524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fentanyl-contaminated cocaine outbreak with laboratory confirmation in New York City in 2019.
    DiSalvo P; Cooper G; Tsao J; Romeo M; Laskowski LK; Chesney G; Su MK
    Am J Emerg Med; 2021 Feb; 40():103-105. PubMed ID: 33360606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Rates of Fentanyl Use Among Psychiatric Emergency Room Patients.
    Elmarasi M; Garcia-Vassallo G; Campbell S; Fuehrlein B
    Am J Addict; 2021 Jan; 30(1):92-95. PubMed ID: 32779217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fentanyl analogue overdose: Key lessons in management in the synthetic opioid age.
    Raheemullah A; Andruska N
    J Opioid Manag; 2019; 15(5):428-432. PubMed ID: 31849033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding opioid overdose risk and response preparedness among people who use cocaine and other drugs: Mixed-methods findings from a large, multi-city study.
    Hughto JMW; Gordon LK; Stopka TJ; Case P; Palacios WR; Tapper A; Green TC
    Subst Abus; 2022; 43(1):465-478. PubMed ID: 34228944
    [No Abstract]   [Full Text] [Related]  

  • 16. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of Fentanyl Positivity Among Urine Drug Test Results Positive for Cocaine or Methamphetamine.
    LaRue L; Twillman RK; Dawson E; Whitley P; Frasco MA; Huskey A; Guevara MG
    JAMA Netw Open; 2019 Apr; 2(4):e192851. PubMed ID: 31026029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal.
    Kilaru AS; Liu M; Gupta R; Perrone J; Delgado MK; Meisel ZF; Lowenstein M
    Am J Emerg Med; 2021 Sep; 47():154-157. PubMed ID: 33812332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourth Wave of Opioid (Illicit Drug) Overdose Deaths and Diminishing Access to Prescription Opioids and Interventional Techniques: Cause and Effect.
    Manchikanti L; Singh VM; Staats PS; Trescot AM; Prunskis J; Knezevic NN; Soin A; Kaye AD; Atluri S; Boswell MV; Abd-Elsayed A; Hirsch JA
    Pain Physician; 2022 Mar; 25(2):97-124. PubMed ID: 35322965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.